Immunocompetent Patients — Live MMR Is Safe
A healthy immune system clears attenuated MMR virus without disease.
- 97%: MMR efficacy, 2 doses (measles protection)
- Live-attenuated: Vaccine type (weakened but replicating)
- 12–15 mo: Standard schedule (then 4–6 yr booster)
- <0.01%: Serious reaction rate (in healthy hosts)
Why live vaccines need working immunity
Attenuated virus still replicates briefly before clearance.
Immune clearance timeline
T-cells and antibodies contain the strain within days.
Baseline screening before dosing
History review confirms no suppression before vaccination.
Chemotherapy Patients — Live Vaccine Contraindicated
Cytotoxic drugs suppress lymphocytes, blocking safe viral clearance.
- During Rx: Contraindication window (plus 3–6 months after)
- High: Neutrophil suppression (chemo cycle dependent)
- 3–6 mo: Post-chemo wait (immune recovery needed)
- Disseminated: Risk if given (vaccine-strain infection)
Cytotoxic suppression mechanism
Chemo kills dividing lymphocytes needed to clear virus.
Timing around treatment cycles
Live vaccines are deferred through active cycles entirely.
Alternatives during suppression
Household contacts get vaccinated instead — cocooning strategy.
HIV With Low CD4 — Disseminated Infection Risk
Low CD4 counts cannot contain the attenuated measles strain.
- ≥200 /µL: CD4 safety threshold (and ≥15% for children)
- <200 /µL: High-risk threshold (live MMR contraindicated)
- Months: ART recovery timeline (to rebuild CD4 count)
- Severe: Disseminated measles risk (can be fatal)
CD4 threshold for live vaccines
Guidelines set 200 cells/µL as the safety cutoff.
Why disseminated infection occurs
Uncontrolled replication spreads vaccine-strain virus systemically.
ART as the recovery pathway
Antiretroviral therapy rebuilds CD4 before vaccination resumes.
Transplant Recipients — Delayed Vaccination Algorithm
Immunosuppressive regimens after transplant require a scheduled delay.
- ≥2 yrs: Solid organ wait (post-transplant minimum)
- ≥24 mo: Stem cell wait (off immunosuppression)
- Extends delay: GVHD complication (graft-versus-host disease)
- ≥4 weeks: Pre-transplant window (before immunosuppression starts)
Fixed algorithmic wait periods
Protocols set minimum delays regardless of symptoms.
Pre-transplant vaccination push
Live vaccines are front-loaded weeks before transplant.
Monitoring immunosuppressive taper
Drug dose reduction is tracked before rechallenge.
Immune Recovery — Vaccination Becomes Safe Again
Restored CD4 and lymphocyte counts reopen the vaccination window.
- Lab-verified: Recovery confirmation (CD4 / counts checked)
- High: Re-vaccination success (once thresholds met)
- Often needed: Repeat dosing (prior immunity may wane)
- 4–8 wks: Follow-up titer check (confirms seroconversion)
Confirming true recovery
Lab values must clear thresholds, not just time elapsed.
Re-vaccination protocol
MMR is re-dosed once immune competence is confirmed.
Long-term surveillance
Titers are rechecked to confirm lasting protection.